Listed

Cellectar Biosciences, Inc.

CLRBNasdaqCIK 1279704HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$7.2m, Q2 FY2026
Net income−$6.9m, Q2 FY2026
Cellectar Biosciences, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Research and development$m7.0Research and development, Q3 FY2023, three months to 2023-09-30$7.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-18, accession 0001410578-24-002012.Report this figure7.7Research and development, Q4 FY2023, three months to 2023-12-31$7.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-13, accession 0001410578-25-000329. Derived: 12-month figure less the 9-month figure.Report this figure7.1Research and development, Q1 FY2024, three months to 2024-03-31$7.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-13, accession 0001410578-25-001205.Report this figure7.3Research and development, Q2 FY2024, three months to 2024-06-30$7.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-14, accession 0001410578-25-001778.Report this figure5.5Research and development, Q3 FY2024, three months to 2024-09-30$5.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-13, accession 0001104659-25-110827.Report this figure6.2Research and development, Q4 FY2024, three months to 2024-12-31$6.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-04, accession 0001104659-26-023167. Derived: 12-month figure less the 9-month figure.Report this figure3.4Research and development, Q1 FY2025, three months to 2025-03-31$3.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-14, accession 0001104659-26-060678.Report this figure2.4Research and development, Q2 FY2025, three months to 2025-06-30$2.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001104659-26-095426.Report this figure2.5Research and development, Q3 FY2025, three months to 2025-09-30$2.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-13, accession 0001104659-25-110827.Report this figure3.2Research and development, Q4 FY2025, three months to 2025-12-31$3.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-04, accession 0001104659-26-023167. Derived: 12-month figure less the 9-month figure.Report this figure3.0Research and development, Q1 FY2026, three months to 2026-03-31$3.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-14, accession 0001104659-26-060678.Report this figure4.6Research and development, Q2 FY2026, three months to 2026-06-30$4.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001104659-26-095426.Report this figure
Operating income$m(9.4)Operating income, Q3 FY2023, three months to 2023-09-30−$9.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-18, accession 0001410578-24-002012.Report this figure(12.5)Operating income, Q4 FY2023, three months to 2023-12-31−$12.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-13, accession 0001410578-25-000329. Derived: 12-month figure less the 9-month figure.Report this figure(12.0)Operating income, Q1 FY2024, three months to 2024-03-31−$12.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-13, accession 0001410578-25-001205.Report this figure(13.7)Operating income, Q2 FY2024, three months to 2024-06-30−$13.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-14, accession 0001410578-25-001778.Report this figure(13.3)Operating income, Q3 FY2024, three months to 2024-09-30−$13.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-110827.Report this figure(12.7)Operating income, Q4 FY2024, three months to 2024-12-31−$12.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-04, accession 0001104659-26-023167. Derived: 12-month figure less the 9-month figure.Report this figure(6.4)Operating income, Q1 FY2025, three months to 2025-03-31−$6.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001104659-26-060678.Report this figure(6.0)Operating income, Q2 FY2025, three months to 2025-06-30−$6.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001104659-26-095426.Report this figure(4.9)Operating income, Q3 FY2025, three months to 2025-09-30−$4.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-110827.Report this figure(5.7)Operating income, Q4 FY2025, three months to 2025-12-31−$5.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-04, accession 0001104659-26-023167. Derived: 12-month figure less the 9-month figure.Report this figure(5.8)Operating income, Q1 FY2026, three months to 2026-03-31−$5.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001104659-26-060678.Report this figure(7.2)Operating income, Q2 FY2026, three months to 2026-06-30−$7.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001104659-26-095426.Report this figure
Net income$m(17.5)Net income, Q3 FY2023, three months to 2023-09-30−$17.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-18, accession 0001410578-24-002012.Report this figure(7.9)Net income, Q4 FY2023, three months to 2023-12-31−$7.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-13, accession 0001410578-25-000329. Derived: 12-month figure less the 9-month figure.Report this figure(26.6)Net income, Q1 FY2024, three months to 2024-03-31−$26.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-110827.Report this figure(0.9)Net income, Q2 FY2024, three months to 2024-06-30−$919.4k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-110827.Report this figure(14.7)Net income, Q3 FY2024, three months to 2024-09-30−$14.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-110827.Report this figure(2.4)Net income, Q4 FY2024, three months to 2024-12-31−$2.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-04, accession 0001104659-26-023167. Derived: 12-month figure less the 9-month figure.Report this figure(6.6)Net income, Q1 FY2025, three months to 2025-03-31−$6.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001104659-26-095426.Report this figure(5.4)Net income, Q2 FY2025, three months to 2025-06-30−$5.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001104659-26-095426.Report this figure(4.4)Net income, Q3 FY2025, three months to 2025-09-30−$4.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-110827.Report this figure(5.3)Net income, Q4 FY2025, three months to 2025-12-31−$5.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-04, accession 0001104659-26-023167. Derived: 12-month figure less the 9-month figure.Report this figure(5.7)Net income, Q1 FY2026, three months to 2026-03-31−$5.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001104659-26-095426.Report this figure(6.9)Net income, Q2 FY2026, three months to 2026-06-30−$6.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001104659-26-095426.Report this figure
Diluted EPS$ per share(1.55)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$1.55 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-18, accession 0001410578-24-002012.Report this figurenot reported(0.91)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.91 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-13, accession 0001410578-25-001205.Report this figure(5.43)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$5.43 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-14, accession 0001410578-25-001778.Report this figure(12.13)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$12.13 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001104659-25-110827.Report this figurenot reported(4.30)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$4.30 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001104659-26-060678.Report this figure(3.39)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$3.39 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001104659-26-095426.Report this figure(1.41)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$1.41 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001104659-25-110827.Report this figurenot reported(1.33)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$1.33 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001104659-26-060678.Report this figure(0.57)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.57 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001104659-26-095426.Report this figure
Basic EPS$ per share(1.55)Basic EPS, Q3 FY2023, three months to 2023-09-30−$1.55 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-18, accession 0001410578-24-002012.Report this figurenot reported(0.91)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.91 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-13, accession 0001410578-25-001205.Report this figure(0.77)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.77 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-14, accession 0001410578-25-001778.Report this figure(11.18)Basic EPS, Q3 FY2024, three months to 2024-09-30−$11.18 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-13, accession 0001104659-25-110827.Report this figurenot reported(4.30)Basic EPS, Q1 FY2025, three months to 2025-03-31−$4.30 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-14, accession 0001104659-26-060678.Report this figure(3.39)Basic EPS, Q2 FY2025, three months to 2025-06-30−$3.39 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001104659-26-095426.Report this figure(1.41)Basic EPS, Q3 FY2025, three months to 2025-09-30−$1.41 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-13, accession 0001104659-25-110827.Report this figurenot reported(1.33)Basic EPS, Q1 FY2026, three months to 2026-03-31−$1.33 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-14, accession 0001104659-26-060678.Report this figure(0.57)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.57 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001104659-26-095426.Report this figure

Balance sheet

Cash and equivalents$34.0m, Q2 FY2026
Shareholders' equity$29.9m, Q2 FY2026
Cellectar Biosciences, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m19.0Cash and equivalents, Q3 FY2023, at 2023-09-30$19.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K/A filed 2024-10-29, accession 0001410578-24-001704.Report this figure9.6Cash and equivalents, FY2023, at 2023-12-31$9.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-13, accession 0001410578-25-000329.Report this figure40.0Cash and equivalents, Q1 FY2024, at 2024-03-31$40.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q/A filed 2024-10-29, accession 0001410578-24-001706.Report this figure25.9Cash and equivalents, Q2 FY2024, at 2024-06-30$25.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-10-29, accession 0001410578-24-001708.Report this figure34.3Cash and equivalents, Q3 FY2024, at 2024-09-30$34.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-18, accession 0001410578-24-002012.Report this figure23.3Cash and equivalents, FY2024, at 2024-12-31$23.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-04, accession 0001104659-26-023167.Report this figure13.9Cash and equivalents, Q1 FY2025, at 2025-03-31$13.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-13, accession 0001410578-25-001205.Report this figure11.0Cash and equivalents, Q2 FY2025, at 2025-06-30$11.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-14, accession 0001410578-25-001778.Report this figure12.6Cash and equivalents, Q3 FY2025, at 2025-09-30$12.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-13, accession 0001104659-25-110827.Report this figure13.2Cash and equivalents, FY2025, at 2025-12-31$13.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001104659-26-095426.Report this figure8.3Cash and equivalents, Q1 FY2026, at 2026-03-31$8.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-14, accession 0001104659-26-060678.Report this figure34.0Cash and equivalents, Q2 FY2026, at 2026-06-30$34.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001104659-26-095426.Report this figure
Current assets$m20.1Current assets, Q3 FY2023, at 2023-09-30$20.1m. XBRL concept us-gaap:AssetsCurrent. 10-K/A filed 2024-10-29, accession 0001410578-24-001704.Report this figure10.5Current assets, FY2023, at 2023-12-31$10.5m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-13, accession 0001410578-25-000329.Report this figure41.4Current assets, Q1 FY2024, at 2024-03-31$41.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q/A filed 2024-10-29, accession 0001410578-24-001706.Report this figure27.9Current assets, Q2 FY2024, at 2024-06-30$27.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-10-29, accession 0001410578-24-001708.Report this figure35.9Current assets, Q3 FY2024, at 2024-09-30$35.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-18, accession 0001410578-24-002012.Report this figure24.3Current assets, FY2024, at 2024-12-31$24.3m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-04, accession 0001104659-26-023167.Report this figure14.9Current assets, Q1 FY2025, at 2025-03-31$14.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-13, accession 0001410578-25-001205.Report this figure12.6Current assets, Q2 FY2025, at 2025-06-30$12.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-14, accession 0001410578-25-001778.Report this figure13.6Current assets, Q3 FY2025, at 2025-09-30$13.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-13, accession 0001104659-25-110827.Report this figure14.0Current assets, FY2025, at 2025-12-31$14.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001104659-26-095426.Report this figure9.3Current assets, Q1 FY2026, at 2026-03-31$9.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-14, accession 0001104659-26-060678.Report this figure34.9Current assets, Q2 FY2026, at 2026-06-30$34.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001104659-26-095426.Report this figure
Total assets$m21.6Total assets, Q3 FY2023, at 2023-09-30$21.6m. XBRL concept us-gaap:Assets. 10-K/A filed 2024-10-29, accession 0001410578-24-001704.Report this figure12.1Total assets, FY2023, at 2023-12-31$12.1m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-13, accession 0001410578-25-000329.Report this figure42.9Total assets, Q1 FY2024, at 2024-03-31$42.9m. XBRL concept us-gaap:Assets. 10-Q/A filed 2024-10-29, accession 0001410578-24-001706.Report this figure29.4Total assets, Q2 FY2024, at 2024-06-30$29.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-10-29, accession 0001410578-24-001708.Report this figure37.3Total assets, Q3 FY2024, at 2024-09-30$37.3m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-18, accession 0001410578-24-002012.Report this figure25.5Total assets, FY2024, at 2024-12-31$25.5m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-04, accession 0001104659-26-023167.Report this figure16.0Total assets, Q1 FY2025, at 2025-03-31$16.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-13, accession 0001410578-25-001205.Report this figure13.7Total assets, Q2 FY2025, at 2025-06-30$13.7m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-14, accession 0001410578-25-001778.Report this figure14.6Total assets, Q3 FY2025, at 2025-09-30$14.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-13, accession 0001104659-25-110827.Report this figure15.0Total assets, FY2025, at 2025-12-31$15.0m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001104659-26-095426.Report this figure11.1Total assets, Q1 FY2026, at 2026-03-31$11.1m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-14, accession 0001104659-26-060678.Report this figure36.6Total assets, Q2 FY2026, at 2026-06-30$36.6m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001104659-26-095426.Report this figure
Current liabilities$m29.8Current liabilities, Q3 FY2023, at 2023-09-30$29.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K/A filed 2024-10-29, accession 0001410578-24-001704.Report this figure25.4Current liabilities, FY2023, at 2023-12-31$25.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-13, accession 0001410578-25-000329.Report this figure28.6Current liabilities, Q1 FY2024, at 2024-03-31$28.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q/A filed 2024-10-29, accession 0001410578-24-001706.Report this figure15.2Current liabilities, Q2 FY2024, at 2024-06-30$15.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-10-29, accession 0001410578-24-001708.Report this figure20.3Current liabilities, Q3 FY2024, at 2024-09-30$20.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-18, accession 0001410578-24-002012.Report this figure9.4Current liabilities, FY2024, at 2024-12-31$9.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-04, accession 0001104659-26-023167.Report this figure6.0Current liabilities, Q1 FY2025, at 2025-03-31$6.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-13, accession 0001410578-25-001205.Report this figure5.9Current liabilities, Q2 FY2025, at 2025-06-30$5.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-14, accession 0001410578-25-001778.Report this figure4.9Current liabilities, Q3 FY2025, at 2025-09-30$4.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-13, accession 0001104659-25-110827.Report this figure4.7Current liabilities, FY2025, at 2025-12-31$4.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001104659-26-095426.Report this figure4.9Current liabilities, Q1 FY2026, at 2026-03-31$4.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-14, accession 0001104659-26-060678.Report this figure5.2Current liabilities, Q2 FY2026, at 2026-06-30$5.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001104659-26-095426.Report this figure
Total liabilities$m30.3Total liabilities, Q3 FY2023, at 2023-09-30$30.3m. XBRL concept us-gaap:Liabilities. 10-K/A filed 2024-10-29, accession 0001410578-24-001704.Report this figure25.9Total liabilities, FY2023, at 2023-12-31$25.9m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-13, accession 0001410578-25-000329.Report this figure29.0Total liabilities, Q1 FY2024, at 2024-03-31$29.0m. XBRL concept us-gaap:Liabilities. 10-Q/A filed 2024-10-29, accession 0001410578-24-001706.Report this figure15.6Total liabilities, Q2 FY2024, at 2024-06-30$15.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-10-29, accession 0001410578-24-001708.Report this figure20.7Total liabilities, Q3 FY2024, at 2024-09-30$20.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-18, accession 0001410578-24-002012.Report this figure9.8Total liabilities, FY2024, at 2024-12-31$9.8m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-04, accession 0001104659-26-023167.Report this figure6.4Total liabilities, Q1 FY2025, at 2025-03-31$6.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-13, accession 0001410578-25-001205.Report this figure6.2Total liabilities, Q2 FY2025, at 2025-06-30$6.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-14, accession 0001410578-25-001778.Report this figure5.2Total liabilities, Q3 FY2025, at 2025-09-30$5.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-13, accession 0001104659-25-110827.Report this figure5.1Total liabilities, FY2025, at 2025-12-31$5.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001104659-26-095426.Report this figure6.4Total liabilities, Q1 FY2026, at 2026-03-31$6.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-14, accession 0001104659-26-060678.Report this figure6.8Total liabilities, Q2 FY2026, at 2026-06-30$6.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001104659-26-095426.Report this figure
Long-term debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m(28.0)Shareholders' equity, Q3 FY2023, at 2023-09-30−$28.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-18, accession 0001410578-24-002012.Report this figure(15.2)Shareholders' equity, FY2023, at 2023-12-31−$15.2m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-04, accession 0001104659-26-023167.Report this figure12.5Shareholders' equity, Q1 FY2024, at 2024-03-31$12.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001104659-25-110827.Report this figure12.4Shareholders' equity, Q2 FY2024, at 2024-06-30$12.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001104659-25-110827.Report this figure15.2Shareholders' equity, Q3 FY2024, at 2024-09-30$15.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001104659-25-110827.Report this figure14.3Shareholders' equity, FY2024, at 2024-12-31$14.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001104659-26-095426.Report this figure8.3Shareholders' equity, Q1 FY2025, at 2025-03-31$8.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001104659-26-095426.Report this figure6.1Shareholders' equity, Q2 FY2025, at 2025-06-30$6.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001104659-26-095426.Report this figure8.0Shareholders' equity, Q3 FY2025, at 2025-09-30$8.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001104659-25-110827.Report this figure8.5Shareholders' equity, FY2025, at 2025-12-31$8.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001104659-26-095426.Report this figure3.3Shareholders' equity, Q1 FY2026, at 2026-03-31$3.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001104659-26-095426.Report this figure29.9Shareholders' equity, Q2 FY2026, at 2026-06-30$29.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001104659-26-095426.Report this figure

Cash flow

Operating cash flow−$6.0m, Q2 FY2026
Capital expenditure$0, Q2 FY2026
Cellectar Biosciences, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(8.1)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$8.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-18, accession 0001410578-24-002012. Derived: 9-month figure less the 6-month figure.Report this figure(9.6)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$9.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-13, accession 0001410578-25-000329. Derived: 12-month figure less the 9-month figure.Report this figure(13.4)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$13.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-13, accession 0001410578-25-001205.Report this figure(14.1)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$14.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-14, accession 0001410578-25-001778. Derived: 6-month figure less the 3-month figure.Report this figure(9.2)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$9.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001104659-25-110827. Derived: 9-month figure less the 6-month figure.Report this figure(10.9)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$10.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-04, accession 0001104659-26-023167. Derived: 12-month figure less the 9-month figure.Report this figure(9.4)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$9.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001104659-26-060678.Report this figure(5.1)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$5.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001104659-26-095426. Derived: 6-month figure less the 3-month figure.Report this figure(4.3)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$4.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001104659-25-110827. Derived: 9-month figure less the 6-month figure.Report this figure(4.3)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$4.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-04, accession 0001104659-26-023167. Derived: 12-month figure less the 9-month figure.Report this figure(4.8)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$4.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001104659-26-060678.Report this figure(6.0)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$6.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001104659-26-095426. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$mnot reported0.3Capital expenditure, Q4 FY2023, three months to 2023-12-31$266.8k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-13, accession 0001410578-25-000329. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2024, three months to 2024-03-31$21.6k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-13, accession 0001410578-25-001205.Report this figure0.0Capital expenditure, Q2 FY2024, three months to 2024-06-30$21.3k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-14, accession 0001410578-25-001778. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-13, accession 0001104659-25-110827. Derived: 9-month figure less the 6-month figure.Report this figure0.1Capital expenditure, Q4 FY2024, three months to 2024-12-31$61.3k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-04, accession 0001104659-26-023167. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reported0.0Capital expenditure, Q1 FY2026, three months to 2026-03-31$3.4k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-14, accession 0001104659-26-060678.Report this figure0.0Capital expenditure, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001104659-26-095426. Derived: 6-month figure less the 3-month figure.Report this figure
Share repurchases$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported

Shares

Diluted shares (weighted)12.23m, Q2 FY2026
Cellectar Biosciences, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares6.1Diluted shares (weighted), Q3 FY2022, three months to 2022-09-306,110,119 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-K/A filed 2024-10-29, accession 0001410578-24-001704.Report this figure11.3Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3111,261,217 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q/A filed 2024-10-29, accession 0001410578-24-001706.Report this figure11.3Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3011,261,217 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-10-29, accession 0001410578-24-001708.Report this figure11.3Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3011,308,738 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-18, accession 0001410578-24-002012.Report this figure29.3Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3129,346,679 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-13, accession 0001410578-25-001205.Report this figure1.2Diluted shares (weighted), Q2 FY2024, three months to 2024-06-301,248,210 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-14, accession 0001410578-25-001778.Report this figure1.3Diluted shares (weighted), Q3 FY2024, three months to 2024-09-301,326,474 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-13, accession 0001104659-25-110827.Report this figure1.5Diluted shares (weighted), Q1 FY2025, three months to 2025-03-311,535,995 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-14, accession 0001104659-26-060678.Report this figure1.6Diluted shares (weighted), Q2 FY2025, three months to 2025-06-301,608,799 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001104659-26-095426.Report this figure3.2Diluted shares (weighted), Q3 FY2025, three months to 2025-09-303,162,040 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-13, accession 0001104659-25-110827.Report this figure4.2Diluted shares (weighted), Q1 FY2026, three months to 2026-03-314,240,129 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-14, accession 0001104659-26-060678.Report this figure12.2Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3012,231,851 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001104659-26-095426.Report this figure

Shares outstanding: 9.45mShares outstanding, period not labelled, at 2026-08-119,452,108 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-13, accession 0001104659-26-095426.Report this figure at Aug 11, 2026, from the cover of the 10-Q filed Aug 13, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:36 ET. Listed shows no prices and gives no investment advice.